GlaxoSmithKline boosted Shingrix educational efforts after seeing administration, storage errors in launch

GlaxoSmithKline boosted Shingrix educational efforts after seeing administration, storage errors in launch

Source: 
Fierce Pharma
snippet: 

Drug launches come with an array of challenges, and GlaxoSmithKline is experiencing that firsthand with its U.S. shingles vaccine rollout. While Shingrix sales are churning ahead of expectations—executives are calling for $600 million in sales this year—officials have tracked some administration and storage errors for the new vaccine.